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Abstract
Background: Although most HTLV infections in Spain have been found in native intravenous drug users carrying
HTLV-2, the large immigration flows from Latin America and Sub-Saharan Africa in recent years may have changed
the prevalence and distribution of HTLV-1 and HTLV-2 infections, and hypothetically open the opportunity for
introducing HTLV-3 or HTLV-4 in Spain. To assess the current seroprevalence of HTLV infection in Spain a national
multicenter, cross-sectional, study was conducted in June 2009.
Results: A total of 6,460 consecutive outpatients attending 16 hospitals were examined. Overall, 12% were
immigrants, and their main origin was Latin America (4.9%), Africa (3.6%) and other European countries (2.8%). Nine
individuals were seroreactive for HTLV antibodies (overall prevalence, 0.14%). Evidence of HTLV-1 infection was
confirmed by Western blot in 4 subjects (prevalence 0.06%) while HTLV-2 infection was found in 5 (prevalence
0.08%). Infection with HTLV types 1, 2, 3 and 4 was discarded by Western blot and specific PCR assays in another
two specimens initially reactive in the enzyme immunoassay. All but one HTLV-1 cases were Latin-Americans while
all persons with HTLV-2 infection were native Spaniards.
Conclusions: The overall prevalence of HTLV infections in Spain remains low, with no evidence of HTLV-3 or HTLV-
4 infections so far.
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Background
Four different types of human T-lymphotropic viruses
(HTLV), named 1-4, have been described in humans.
HTLV-1, the first human retrovirus was identified in
1980; it is the etiological agent of adult T-cell leukemia/
lymphoma (ATLL) [1] and tropical spastic paraparesis/
HTLV-1 associated myelopathy (TSP/HAM) [2]. These
illnesses fortunately only affect to less than 10% of
infected individuals lifetime. HTLV-2 was identified in
1982; it has occasionally been associated with subacute
neurological syndromes resembling TSP/HAM [3] with
no evidence of producing hematological malignancies
[4]. Finally, HTLV-3 and HTLV-4 were described in
2005 in a few asymptomatic individuals from Cameroon
and to date no illnesses have been associated with these
viral infections [5-8].
The main routes of transmission of HTLV are from
infected mothers to their newborns, especially through
prolonged breast-feeding, sexual intercourse, blood
transfusion and sharing of needles and syringes between
intravenous drug users [9]. HTLV-1 has spread world-
wide with estimates of 10-20 million infected people. It
is endemic in some parts of Japan, Central and South
America and Sub-Saharan Africa [10]. In contrast,
HTLV-2 infection affects 3-5 million persons and is pre-
valent in some Amerindian and African pygmy tribes
and epidemic among injecting drug users in Western
Europe and North America [4]. In Spain, the majority of
individuals HTLV positive are native Spaniards, most of
them with past history of intravenous drug use and
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infected with HTLV-1, which is overall less prevalent,
are immigrants coming from endemic regions in Central
and South America [11-13]. Until December 2009, a
total of 144 cases of HTLV-1 infection and 717 of
HTLV-2 infection had been recorded at the national
Spanish HTLV registry [13].
Several serological surveys conducted over the last
decade have monitored the prevalence of HTLV infec-
tions in Spain [14]. In the last serosurvey conducted in
year 2008, a total of 7 out of 5,742 consecutive hospital
outpatients were found to be HTLV-seroreactive (overall
rate, 0.12%). No single case of HTLV-1 infection was
reported at that time [15].
Recent estimates have pointed out that the number of
immigrants legally registered as living in Spain has
increased more than six-fold over the last 10 years [16].
Immigrants currently represent nearly 6 out of 47 mil-
lion people in Spain. Many of the foreigners come from
regions where the presence of HTLV-1 is endemic as
some countries in Latin-America and Sub-Saharan
Africa and where HTLV-3 and HTLV-4 have been
reported occasionally [8]. This wave of immigration
could have modified the prevalence of HTLV infection
in Spain and the type distribution. In order to test this
hypothesis, the Spanish HTLV Group conducted a new
prospective, multicenter, national serosurvey for study-
ing HTLV infection in year 2009.
Results
A total of 6,460 consecutive adult outpatients attended
during June 2009 at 16 distinct hospitals were screened
for HTLV antibodies. The median age of the study
population was 38 years and 40% were male. Although
native Spaniards represented 88% of the total study
population, 4.9% of subjects come from Latin America,
3.6% from Africa and 2.8% from other European
countries.
Nine specimens were repeatedly EIA reactive and were
confirmed by Western blot as HTLV-1 positive (n = 4)
and HTLV-2 (n = 5). Another two samples exhibited
EIA reactivity close to the cut-off but could not be con-
firmed as HTLV positive by Western blot or PCR test-
ing. No PBMCs could be obtained from the four HTLV-
1 positive cases, which precluded further virological
characterization of these samples.
The prevalence of HTLV found in this study was
0.14%, being 0.06% for HTLV-1 and 0.08% for HTLV-2.
Neither HTLV-3 nor HTLV-4 were found in this survey.
Three of the HTLV-1 carriers had been born in Latin
America (Peru, Ecuador and the Dominican Republic)
w h i l et h el a s to n ew a sa3 1y e a r s - o l dn a t i v eS p a n i s h
woman who denied any significant risk behavior for
HTLV exposure, including intravenous drug use, sexual
promiscuity, transfusions or stages in Latin America. All
HTLV-1 carriers but one were asymptomatic. The
woman from the Dominican Republic was newly diag-
nosed with mild TSP/HAM (Table 1).
In contrast to HTLV-1 cases, all 5 subjects with
HTLV-2 infection identified in this study were native
Spaniards who admitted prior intravenous drug use.
Moreover, all were coinfected with HIV. None of them
complained of neurological symptoms potentially asso-
ciated with HTLV-2 (Table 1).
The prevalence of HTLV infection in the current
study seems to remain fairly stable (Table 2). Moreover,
no cases of HTLV-3 nor HTLV-4 have been identified
so far in Spain.
Discussion
For several years, periodic surveillance studies have been
conducted in Spain looking for changes in the rate and
Table 1 Main characteristics of HTLV EIA reactive individuals
Patient
No.
HTLV
type
Age
(years)
Gender Country of origin Risk group HTLV-associated illness HIV
1 1 31 female Spain heterosexual none negative
2 1 60 female Peru transfusion TSP/HAM negative
3 1 41 female Dominican Republic heterosexual none negative
4 1 36 male Ecuador homosexual none positive
5 2 51 male Spain intravenous drug user none positive
6 2 41 male Spain intravenous drug user none positive
7 2 42 male Spain intravenous drug user none positive
8 2 47 female Spain intravenous drug user none positive
9 2 41 male Spain intravenous drug user none positive
10* No 44 female Venezuela heterosexual none negative
11* No 37 female Spain heterosexual none positive
*Indeterminate Western blot pattern
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lence of HTLV infection found in this study was low
(0.14%) and similar to that found in previous serosur-
veys carried out in Spain [14,15]. Only 9 out of 6,460
tested individuals were found to be positive for HTLV.
While HTLV-2 seems to have been present for decades
among native Spanish intravenous drug users [17],
HTLV-1 seems to have been introduced more recently.
The four cases identified in the current study support
that the recent big wave of immigration from HTLV-1
endemic regions in Latin America and Africa, could
have contributed to introduce HTLV-1 infection in
Spain. Moreover, the recognition of HTLV-1 in a native
Spaniard with lack of any evident risk for HTLV-1 expo-
sure might further support that HTLV-1 is already
spreading within the native Spanish population. In other
European countries, as the United Kingdom and France,
with larger and longer presence of immigrants from
HTLV-1 endemic regions, sexual transmission of
HTLV-1 from foreigners to natives has already been
well documented [18].
The recognition of HTLV-1 infected persons in Spain
has several clinical and public health implications.
HTLV testing should be considered for a broader num-
ber of persons and conditions, including blood bank
donors, organ transplantation, antenatal testing or sexu-
ally transmitted diseases clinics. Close relatives of
infected individuals should be offered for HTLV testing.
Given that most HTLV-1 carriers would remain asymp-
tomatic life long, unaware silent transmission of the
virus is the most worrisome. Wider HTLV testing may
allow identification of carriers and help to reduce
further transmission. Pregnant women with HTLV-1
infection should be advised against breast-feeding, which
is the most effective way to prevent vertical HTLV-1
transmission. Moreover, physicians must monitor peri-
odically asymptomatic persons known to be infected
with HTLV-1, in order to facilitate early recognition of
classical complications, such as TSP/HAM or ATL.
Attention to mild symptoms or laboratory abnormalities,
as in one of the current cases complaining minimal
paraparesis, may permit early diagnosis and better treat-
ment options.
The rate of HTLV-2 infection seems to remain fairly
stable in Spain and confined mainly to former intrave-
nous drug users and their sexual partners. As most
HTLV-2 carriers are intravenous drug users coinfected
with HIV and intravenous drug use practices have dra-
matically declined in Spain [19], we should expect a
steadily decline in the prevalence of HTLV-2 infection
in coming years.
It is worth to note that this is the largest study carried
out in Spain examining the prevalence of HTLV infec-
tions. We are confident that the 16 hospitals that parti-
cipated in the study properly covered the whole country.
However, testing was made on hospital outpatients and
therefore bias exists in terms of extrapolation of preva-
lence rates to the entire population. Studies conducted
in other populations, including pregnant women, blood
donors, immigrants, sexually transmitted disease clinics,
would help to define more accurately the extent of
HTLV infections in Spain. Of note, despite testing a
relatively large immigrant population from Western
Africa, where HTLV-3 and HTLV-4 were described ori-
ginally [5-7] no single case of infection with these
HTLV variants has been reported so far in Spain. In this
study, the two samples from individuals showing weak
EIA reactivity and indeterminate western blot results
were negative for HTLV-3 and HTLV-4 testing. More-
over, they had no epidemiological link with Africa,
being these two women from Venezuela and Spain,
respectively. These results are in agreement with those
from the United States, where a recent report has failed
to identify HTLV-3 and/or HTLV-4 infection in risk
groups, including individuals harboring indeterminate
HTLV western blot patterns [20]. Although all indivi-
duals reported to date as infected with HTLV-3 or
HTLV-4 have displayed reactivity on EIA designed for
HTLV-1 and HTLV-2 screening [5,21], we should
acknowledge that the overall sensitivity of these tests to
pick up all HTLV-3 and/or HTLV-4 antibodies is cur-
rently unknown [22]. Thus, misdiagnosis of HTLV-3
and/or HTLV-4 in the present study might have
occurred.
Conclusions
This study supports that the prevalence of HTLV
i n f e c t i o ni nS p a i nr e m a i n ss t a b l ea n dl o w .H o w e v e r
there is a slightly trend towards an increase in HTLV-
1m a i n l yd r i v e nb yt h el a r g ei m m i g r a t i o nf r o me n d e -
mic regions in Latin America over the last decades.
Table 2 Main characteristics of the two last cross-
sectional surveys of HTLV antibodies conducted in Spain
Survey Year 2008
15
(n = 5,742)
2009
(n = 6,460)
p
Male gender (%) 41.2 40
Median age, years (IQR) 40 (31-57) 38 (29-53)
Origin (%)
Spain 92 88
Latin America 3.4 4.9
Africa 1.9 3.6
Asia 0.2 0.6
Other European countries 2.5 2.8
HTLV (n, %) 7 (0.12) 9 (0.14) 0.9
HTLV-1 0 (0) 4 (0.06) 0.08
HTLV-2 7 (0.12) 5 (0.08) 0.62
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in recent years may result in a steadily decline in
HTLV-2 in the near future. Altogether, HTLV-1 must
be expected to take over HTLV-2 in coming years.
Given that HTLV-1 is more pathogenic and that trans-
mission often occurs from people unaware of their
infection, HTLV testing should be considered for a
broader number of persons.
Methods
All adult outpatients attending the hospitals belonging
to the HTLV Spanish Network, were invited consecu-
tively during June 2009 to be tested for HTLV antibo-
dies. In order to make sampling representative, the
hospitals selected were distributed geographically across
Spain and each of them recruited at least 350 samples.
Every participating centre obtained approval from the
corresponding ethical committee and informed consent
was obtained from all recruited individuals.
Pools of five sera were screened for HTLV antibodies
using a commercial enzyme immunoassay (EIA)
(Murex HTLV I + II, Abbott, Madrid, Spain). This
strategy has been evaluated previously and considered
as appropriated for HTLV antibody testing [23]. Sera
from reactive pools were re-tested individually by EIA
and confirmed using a commercial Western blot (Gen-
elabs Diagnostics, Redwood City, CA). Band patterns
were interpreted following the HERN criteria [24].
Briefly, HTLV-1 or HTLV-2 positivity was considered
when reactivity to at least two recombinant envelope
bands (rgp21 and rgp46-I or II, respectively) and the
gag band p24 were present. In samples yielding inde-
terminate Western blot pattern, when possible a new
blood sample was drawn and peripheral blood mono-
nuclear cells were obtained. Then, genetic confirma-
tion discarded or confirmed HTLV infections using
specific primers for HTLV types 1-4. Briefly, DNA was
extracted from PBMCs with the midi spin columns
from the QIAamp DNA blood Midi kit (Qiagen), using
the procedure recommended by the manufacturer.
Afterwards, polymerase chain reactions (PCR) were
carried out on genomic LTR and/or pol regions, using
primers and conditions described elsewhere [17,18,25].
The presence of amplicons was checked with electro-
phoresis on agarose gels. Finally, medical records were
retrospectively reviewed for all individuals found to be
HTLV positives.
Statistical analysis
Results are given as proportions and median values.
Comparisons were made using the chi square test, with
Fisher correction when appropriated. Differences were
considered to be significant only when p values were
lower than 0.05. All analyses were performed using
SPSS version 11.0 (SPSS Inc., Chicago, IL).
HTLV Spanish study group
C. Rodríguez and J. del Romero (Centro Sanitario
Sandoval, Madrid); C. Tuset, G. Marcaida and T. Tuset
(Hospital General Universitario, Valencia); E. Caballero
and I. Molina (Hospital Vall d’Hebron, Barcelona); A.
A g u i l e r a ,J . J .R o d r í g u e z - C a l v i ñ o ,S .C o r t i z oa n dB .R e g -
ueiro (Hospital Conxo-CHUS, Santiago); R. Benito and
M. Borrás (Hospital Clínico Universitario Lozano Blesa,
Zaragoza); R. Ortiz de Lejarazu and J.M. Eiros (Hospital
Clínico Universitario, Valladolid); J.M. Miró, C. Man-
zardo, M.M. Gutiérrez and T. Pumarola (Hospital
Clínic-IDIBAPS, Barcelona); J. García and I. Paz (Hospi-
tal Cristal-Piñor, Orense); E. Calderón, F.J. Medrano and
M. Leal (Hospital Virgen del Rocío, Sevilla; CIBER de
Epidemiología y Salud Pública); F. Capote (Hospital
Puerta del Mar, Cádiz); A. Vallejo, F. Dronda and S.
Moreno (Hospital Ramón y Cajal, Madrid); D. Escudero
(Hospital Germans Trias i Pujol, Barcelona); E. Pujol
(Hospital Juan Ramón Jiménez, Huelva); M. Trigo, J.
Diz, P. Álvarez and M. García-Campello (Complejo
Hospitalario, Pontevedra); M. Rodríguez-Iglesias (Hospi-
tal Universitario Puerta del Mar, Cádiz); A.M. Martín
and A. Hernandez-Betancor (Hospital Universitario
Insular, Las Palmas de Gran Canaria); J.M. Ramos, J. C.
Rodríguez and F. Gutiérrez (Hospital General, Elche); C.
Gómez-Hernando (Complejo Hospitalario Virgen de la
Salud, Toledo); A. Guelar (Hospital del Mar, Barcelona);
G. Cilla and E. Pérez-Trallero (Hospital Donostia, San
Sebastián); J. López-Aldeguer (Hospital La Fe, Valencia);
J. Sola (Hospital de Navarra, Pamplona); L. Fernández-
Pereira (Hospital San Pedro de Alcántara, Cáceres); J.
Niubó (Ciudad Sanitaria de Bellvitge, Barcelona); S.
Veloso (Hospital Universitario, Tarragona); J.L. Gómez
Sirvent, L. Arroyo, M.M. Alonso, M.R. Alemán and D.
García Rosado (Hospital Universitario de Canarias,
Santa Cruz de Tenerife); L. Force (Hospital General,
Mataró); C. Cifuentes (Hospital Son Llatzer, Palma de
Mallorca); J. García (Hospital de León); S. Pérez (Hospi-
t a ld oM e i x o e i r o ,V i g o ) ;C .R a y a( H o s p i t a ld e lB i e r z o ,
Ponferrada); A. González-Praetorius (Hospital Universi-
tario, Guadalajara); A. Mena, J.L. Pérez and M. Peñar-
anda (Hospital Son Dureta, Mallorca); J.M. Montejo
(Hospital de Cruces, Bilbao); N. Margall, M. Gutiérrez,
P. Domingo (Hospital de Sant Pau, Barcelona); L. Roc
and A. Martinez Sapiña (Hospital Miguel Servet, Zara-
goza); I. Viciana (Hospital Virgen de la Victoria,
Málaga); T. Cabezas, A. B. Lozano and J.M. Fernandez
(Hospital de Poniente, Almería); I. García and G. Gaspar
(Hospital Universitario de Getafe, Madrid); R. García
and M. Gorgolas (Fundación Jiménez Díaz, Madrid); A.
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pital Carlos III, Madrid).
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